Primary MM tumor samples
. | Viable cells, as % of control . | . | . | |
|---|---|---|---|---|
| Patient no., drugs . | With IL-6 . | With BMSCs . | Stage . | |
| 1, D/3A/3B | 100/27/83 | 100/13/89 | IIIA | |
| 2, D/3A/3B | 100/27/70 | 100/36/88 | IIIA | |
| 3, D/3A/3B | NA | 100/72/100 | IIIA | |
| 4, D/3A/3B | 100/80/80 | 100/78/99 | IIIA | |
| 5, D/3A/3B | 100/7/97 | 100/70/97 | IIB | |
| 6, D/3A/3B | 100/9/86 | 100/28/91 | IIIA | |
| 7, D/3A/3B | NA | 100/10/72 | IIIB | |
| 8, D/3A/3B | 100/27/91 | 100/72/102 | IIIA | |
| 9, D/3A/3B | NA | 100/98/112 | IIIA | |
| 10, D/3A/3B | 100/56/103 | 100/90/102 | IIIA | |
| 11, D/3A/3B | 100/2/84 | 100/39/98 | IIIA | |
| 12, D/3A/3B | NA | 100/75/69 | IIIB | |
| 13, D/3A/3B | 100/14/92 | 100/18/96 | IIIA | |
| 14 | IIIA | |||
| D/3A/3B | NA | 100/59/127 | ||
| Eto | ND | 87 | ||
| Mel | ND | 49 | ||
| 15 | IIA | |||
| D/3A/3B | 100/6/92 | 100/25/93 | ||
| Eto | ND | 61 | ||
| Mel | ND | 32 | ||
| 16 | IIIA | |||
| D/3A/3B | 100/45/99 | 100/50/93 | ||
| Eto | ND | 74 | ||
| Mel | ND | 42 | ||
| 17 | IA | |||
| D/3A/3B | 100/10/87 | 100/40/92 | ||
| Eto | ND | 101 | ||
| Mel | ND | 86 | ||
| 18 | IIIA | |||
| D/3A/3B | NA | 100/40/92 | ||
| Eto | ND | 92 | ||
| Mel | ND | 61 | ||
| 19, D/3A/3B | 100/8/69 | 100/10/88 | IIIA | |
| 20, D/3A/3B | NA | 100/12/110 | IIIA | |
| 21 | IIIA | |||
| D/3A/3B | NA | 100/48/104 | ||
| Eto | ND | 98 | ||
| Mel | ND | 43 | ||
| 22 | IIIA | |||
| D/3A/3B | NA | 100/61/97 | ||
| Eto | ND | 75 | ||
| Mel | ND | 61 | ||
| 23 | IIA | |||
| D/3A/3B | 100/13/88 | 100/25/86 | ||
| Eto | ND | 71 | ||
| Mel | ND | 53 | ||
| 24 | IIIA | |||
| D/3A/3B | 100/14/88 | 100/48/99 | ||
| Eto | ND | 89 | ||
| Mel | ND | 40 | ||
| 25 | IIIA | |||
| D/3A/3B | NA | 100/38/112 | ||
| Eto | ND | 73 | ||
| Mel | ND | 24 | ||
. | Viable cells, as % of control . | . | . | |
|---|---|---|---|---|
| Patient no., drugs . | With IL-6 . | With BMSCs . | Stage . | |
| 1, D/3A/3B | 100/27/83 | 100/13/89 | IIIA | |
| 2, D/3A/3B | 100/27/70 | 100/36/88 | IIIA | |
| 3, D/3A/3B | NA | 100/72/100 | IIIA | |
| 4, D/3A/3B | 100/80/80 | 100/78/99 | IIIA | |
| 5, D/3A/3B | 100/7/97 | 100/70/97 | IIB | |
| 6, D/3A/3B | 100/9/86 | 100/28/91 | IIIA | |
| 7, D/3A/3B | NA | 100/10/72 | IIIB | |
| 8, D/3A/3B | 100/27/91 | 100/72/102 | IIIA | |
| 9, D/3A/3B | NA | 100/98/112 | IIIA | |
| 10, D/3A/3B | 100/56/103 | 100/90/102 | IIIA | |
| 11, D/3A/3B | 100/2/84 | 100/39/98 | IIIA | |
| 12, D/3A/3B | NA | 100/75/69 | IIIB | |
| 13, D/3A/3B | 100/14/92 | 100/18/96 | IIIA | |
| 14 | IIIA | |||
| D/3A/3B | NA | 100/59/127 | ||
| Eto | ND | 87 | ||
| Mel | ND | 49 | ||
| 15 | IIA | |||
| D/3A/3B | 100/6/92 | 100/25/93 | ||
| Eto | ND | 61 | ||
| Mel | ND | 32 | ||
| 16 | IIIA | |||
| D/3A/3B | 100/45/99 | 100/50/93 | ||
| Eto | ND | 74 | ||
| Mel | ND | 42 | ||
| 17 | IA | |||
| D/3A/3B | 100/10/87 | 100/40/92 | ||
| Eto | ND | 101 | ||
| Mel | ND | 86 | ||
| 18 | IIIA | |||
| D/3A/3B | NA | 100/40/92 | ||
| Eto | ND | 92 | ||
| Mel | ND | 61 | ||
| 19, D/3A/3B | 100/8/69 | 100/10/88 | IIIA | |
| 20, D/3A/3B | NA | 100/12/110 | IIIA | |
| 21 | IIIA | |||
| D/3A/3B | NA | 100/48/104 | ||
| Eto | ND | 98 | ||
| Mel | ND | 43 | ||
| 22 | IIIA | |||
| D/3A/3B | NA | 100/61/97 | ||
| Eto | ND | 75 | ||
| Mel | ND | 61 | ||
| 23 | IIA | |||
| D/3A/3B | 100/13/88 | 100/25/86 | ||
| Eto | ND | 71 | ||
| Mel | ND | 53 | ||
| 24 | IIIA | |||
| D/3A/3B | 100/14/88 | 100/48/99 | ||
| Eto | ND | 89 | ||
| Mel | ND | 40 | ||
| 25 | IIIA | |||
| D/3A/3B | NA | 100/38/112 | ||
| Eto | ND | 73 | ||
| Mel | ND | 24 | ||
“Viable cells, as % of control” refers to the percentage of live cells after a 5-day drug treatment relative to controls treated with DMSO (set as 100%) in medium supplemented with 10 ng/mL IL-6 or in coculture with BMSCs. Concentration of each drug was 10 μM. D/3A/3B indicates DMSO/nutlin-3a/nutlin-3b; NA, not applicable (survival in control <35% of total cells); ND, not determined; Eto, etoposide; Mel, melphalan.